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Abstract
Carbamazepine and imipramine are drugs that have significant binding to human serum albumin
(HSA), the most abundant serum protein in blood and a common transport protein for many drugs
in the body. Information on the kinetics of these drug interactions with HSA would be valuable in
understanding the pharmacokinetic behavior of these drugs and could provide data that might lead
to the creation of improved assays for these analytes in biological samples. In this report, an
approach based on peak profiling was used with high-performance affinity chromatography to
measure the dissociation rate constants for carbamazepine and imipramine with HSA. This
approach compared the elution profiles for each drug and a non-retained species on an HSA
column and control column over a board range of flow rates. Various approaches for the
corrections of non-specific binding between these drugs and the support were considered and
compared in this process. Dissociation rate constants of 1.7 (± 0.2) s-1 and 0.67 (± 0.04) s-1 at pH
7.4 and 37 °C were estimated by this approach for HSA in its interactions with carbamazepine and
imipramine, respectively. These results gave good agreement with rate constants that have
determined by other methods or for similar solute interactions with HSA. The approach described
in this report for kinetic studies is not limited to these particular drugs or HSA but can also be
extended to other drugs and proteins.
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Peak profiling; High-performance affinity chromatography; Carbamazepine; Imipramine; Human
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1. INTRODUCTION
Human serum albumin (HSA) is the most abundant protein in serum [1]. This protein has a
molar mass of 66.5 kDa and is known to have reversible binding to a large number of drugs,
hormones and other small solutes in the circulation. This binding is important in determining
the transport, excretion and metabolism of such substances in the body [1,2]. The kinetics of
these interactions can also be important in determining the distribution and metabolic half-
life of drugs [1].
Carbamazepine and imipramine (see Figure 1) are two drugs that are known to have
significant binding to HSA. Carbamazepine is used to treat seizures and bipolar disorder and
has an affinity for HSA in the range of 10-3–10-4 M-1 [3-5], with this binding occurring at a
single site on HSA (i.e., Sudlow site II) with an association equilibrium constant of 5.3 ×
103 M−1 at pH 7.4 and 37 °C [5]. Imipramine is a tricyclic antidepressant [6] that also binds
to Sudlow site II of HSA, but which has an association equilibrium constant at this site of
1.6 × 105 M-1 [7]. Although the strength of these drug interactions with HSA has been
considered in a number of previous reports [3-5,7], there is little information on the kinetics
of these interactions. Obtaining such kinetic information could be useful in providing a
better understanding of the behavior of these drugs in the body [2,8].
There are several techniques that are used to examine the rates of solute-protein interactions,
including surface plasmon resonance (SPR), stopped flow techniques, filtration assays, and
various chromatographic methods [9-13]. SPR is best suited for use with systems that have
moderate to strong affinities, stopped flow techniques require solutes or interactions that can
be measured by methods such as fluorescence, and filtration assays have limited sampling
rates [11-13]. Chromatographic techniques based on high-performance affinity
chromatography (HPAC) and band-broadening measurements, peak decay analysis or the
split peak method have also been reported for kinetic studies; however, these methods have
limitations as well [10,14-20]. Band-broadening studies work well for systems that have fast
association and dissociation kinetics but require the precise measurement of peak variances
on multiple columns and at many flow rates [14-20]. Peak decay analysis is more suitable
for systems with moderate rates of dissociation if mobile phase mass transfer is negligible,
which generally requires work with small columns and high flow rates [10,20]. The split
peak method makes use of peak area measurements of a non-retained analyte fraction to
determine association rate constants; this approach works best for systems with strong
binding and slow dissociation kinetics and again typically requires the use of small columns
and high flow rates [17,21].
One variation on the band-broadening method in HPAC that has been of interest in recent
studies of solute-protein binding is an approach known as peak profiling [9,10,22]. In this
method, band-broadening measurements are made for both the solute of interest and a non-
retained solute on an affinity column that contains a binding agent. This information is then
used along with chromatographic theory to estimate the dissociation rate constant for the
retained solute as it interacts with the binding agent. It has been shown in work with model
systems that this approach can be used to examine the interactions of solutes with HSA [22],
making this method attractive for measuring drug dissociation rates from this protein. This
previous work included a validation versus reference techniques for an analyte (i.e., L-
tryptophan) that is similar to carbamazepine in its affinity for HSA and that has the same
binding site on this protein as both carbamazepine and imipramine [5,7,9,10,16,22]. In this
current study, the peak profiling method will be used to examine the binding of
carbamazepine and imipramine with HSA. It will be shown as part of this work how peak
profiling can be used to correct for the non-specific binding of these and other drugs to a
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chromatographic support, as achieved by expanding the theory of this approach to include
systems with multi-site interactions.
2. THEORY
Eqn. (1) shows the reversible reaction model that was used in this study to describe the
binding of a drug or small solute (A) with an immobilized binding agent or protein (P)
[22,23]. In this model, the association equilibrium constant (Ka) is equal to ratio of the
second-order association rate constant (ka) and the first-order dissociation rate constant (kd)
for the binding of A with P.
(1)
A similar reversible model was used to describe the binding of A with non-specific sites on
a support.
In the peak profiling method, the first and second statistical moments for an injected analyte
are used to determine the retention time and variance for this solute on a column containing
P. The variance is, in turn, related to the various band-broadening processes that occur
during passage of A through the column, such as eddy diffusion, mobile phase mass transfer,
stagnant mobile phase mass transfer, longitudinal diffusion, and stationary phase mass
transfer [22,24].
Most previous work with the peak profiling method has been carried out by using
measurements at a single flow rate under conditions in which stationary phase mass transfer
is the dominant source of band-broadening. Under such conditions, the measured retention
time and variance of the retained analyte, as well as the elution time and variance of a non-
retained species, can be used with Eqn. (2) to estimate the value of the dissociation rate
constant kd for the interaction of A with P [9,25].
(2)
The terms tR and σR2 in this equation are the retention time and variance of the peak for the
injected analyte, while tM and σR2 are the void time and variance of the peak for the non-
retained species. This method not only requires that stationary phase mass transfer be the
main source of band-broadening, but Eqn. (2) also assumes that all other sources of band-
broadening are negligible or the same for the retained and non-retained species [9,10,22].
It has been shown recently that the peak profiling approach can be used over a broader range
of flow rates by using the following form of Eqn. (2) [9,10,22].
(3)
In this expression, HR is the total plate height measured for analyte A on a column
containing binding agent P, and HM is the total plate height measured on the same column
for a non-retained solute. The term k is the retention factor for the analyte, u is the linear
velocity of the mobile phase, and Hk is the plate height contribution due to stationary phase
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mass transfer. According to Eqn. (3), a plot of (HR – HM) versus u k/(1+k)2 should result in
a linear relationship, with a best-fit slope that will give the value of kd if all sources of band-
broadening other than Hk are negligible or approximately the same for the analyte and non-
retained solute.
Both Eqns. (2) and (3) are for a model in which there is only one type of binding site for the
analyte in the column. However, it is possible to expand these relationships for use with a
two-site model, as shown in Eqn. (4) (see derivation provided in the Supplemental
Information) [26].
(4)
In this particular set of equations, the two-site model is used to describe an analyte with
specific binding to HSA (i.e., representing P in Eqn. (1)) as well as non-specific binding by
the same analyte to the support. The term kd,HSA in this case represents the dissociation rate
constant for the analyte with HSA. The term kHSA is the retention factor for the analyte that
is due to the interactions of A with HSA, and αHSA is the fraction of the total retention factor
that is due to the binding of A with HSA. The term kd,n represents the dissociation rate
constant for A with its non-specific sites, kn is the retention factor for A that is due to this
non-specific binding, and αn is the fraction of the total retention factor that is due to this
non-specific binding. Eqn. (4) again predicts a linear relationship for a plot of (HR – HM)
versus u k/(1+k)2 in a two-site system, but the slope of this plot will now be influenced by
the dissociation rate constants for the analyte at its various binding sites as well as the
degree of analyte retention that is created by each of these interactions.
If the second type of interaction in a two-site model is due to non-specific binding of the
analyte to the support, as is illustrated in Eqn. (4), the dissociation rate constant and
retention factor for this interaction can be obtained through independent peak profiling
studies for the analyte on a control column. The retention data obtained on the control
column can then also be used with the retention data from a column containing binding
agent P (i.e., HSA in this study) to estimate the values of αHSA and αn in Eqn. (4) [24]. For
example, the total retention factor k for an analyte on an HSA column can be described by
Eqn. (5),
(5)
in which fHSA is the fraction of the column surface area that occupied by the immobilized
HSA. This latter value can be estimated by using the measured protein content of the
support and the approximate dimensions of HSA (or P) [27]. The values of αn and αHSA can
then be found by using the following expressions.
(6)
(7)
By using this set of equations, it is possible to use the peak profiling results obtained on both
an HSA and a control column to correct for the effects of non-specific binding and to
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estimate the dissociation rate constant for the analyte with HSA, as will be illustrated in
Section 4 using carbamazepine and imipramine as examples.
3. EXPERIMENTAL
3.1. Reagents
The HSA (Cohn fraction V, essentially fatty acid free, ≥ 96% pure), carbamazepine and
imipramine were obtained from Sigma-Aldrich (St. Louis, MO). The Nucleosil Si-300 silica
(7 μm particle diameter, Ǻ pore size) was purchased from Macherey Nagel (Düren,
Germany). Reagents for the bicinchoninic acid (BCA) protein assay were from Pierce
(Rockford, IL). All other chemicals used were reagent-grade or better. All aqueous solutions
were prepared with water obtained from a Nanopure water system (Barnstead, Dubuque, IA)
and filtered by using Osmonics 0.22 μm nylon filters from Fisher (Pittsburgh, PA).
3.2. Apparatus
The chromatographic system consisted of a LC-10AD pump, a SPD-10AV UV/Vis detector,
and an SCL-10A system controller (Shimadzu, Columbia, MD). Samples were injected by
using a SpectraSystem AS3000 autosampler (Thermo separations, Waltham, MA) equipped
with a 5 μL sample loop. All columns and mobile phases were maintained at a constant
temperature of 37.0 (± 0.1) °C by using a water jacket from Alltech (Deerfield, IL) and a
9100 circulating water bath from Fisher. The columns were downward slurry-packed by
using an HPLC column slurry packer from Alltech. Chromatographic data were collected
using programs written in LabView 5.0 or 8.0 (National Instruments, Austin, TX) and were
analyzed using PeakFit 4.12 (Systat Software, San Jose, CA).
3.3. Column Preparation
The Nucleosil Si-300 was converted into diol-bonded silica, as described previously [28].
The diol coverage of the resulting support was 235 (± 20) μmol diol groups (± 1 S.D.) per
gram of silica, as determined by an iodometric capillary electrophoresis assay [29]. HSA
was immobilized onto the diol-bonded silica by using the Schiff base method [30]. A control
support was made from the same batch of diol-bonded silica by using the Schiff base
method but with no HSA being added during the immobilization step. The final HSA
supports used in this work contained 47 (± 3) to 57 (± 3) mg HSA per gram of silica, as
determined in triplicate by a BCA protein assay using HSA as the standard and the control
support as the blank [31]. The HSA support and control support were downward slurry-
packed at 24-28 MPa (3500-4000 psi) into separate 5 cm × 4.6 mm i.d. stainless steel
columns using pH 7.4, 0.067 M potassium phosphate buffer as the packing solution. These
columns were stored at 4 °C in pH 7.4, 0.067 M potassium phosphate buffer when not in
use.
3.4. Chromatographic Experiments
The mobile phase used in this study was pH 7.4, 0.067 M potassium phosphate buffer. The
samples each drug or sodium nitrate (i.e., which was used as a non-retained solute in this
study) were prepared in this mobile phase. All chromatographic studies were carried out in
triplicate. The elution of carbamazepine, imipramine, and sodium nitrate was monitored at
285 nm, 205 nm, or 205 nm, respectively. All experiments were performed within one year
of column preparation and each column was used for less than 220 injections. Previous
studies have shown that similar HSA columns are stable and show no significant signs of
degradation under these conditions [16].
The final peak profiling experiments were performed by injecting 30 μM carbamazepine,
25-30 μM sodium nitrate, or 100 μM imipramine on the HSA column, control column, and a
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zero volume spacer/union at flow rates ranging from 1.0 to 4.0 ml/min. These sample
concentrations were selected through studies such as those described in Section 4.1 and were
based on conditions and guidelines that have been identified previously as being suitable for
use in peak profiling [22]. The retention time (i.e., first statistical moment) and variance
(second statistical moment) of each chromatographic peak were obtained by using Peakfit
4.12 with an exponentially-modified Gaussian (EMG) fit and the linear progressive baseline
plus residual options of this program.
4. RESULTS AND DISCUSSION
4.1. Selection of Conditions for Peak Profiling
Several factors were considered in selecting the conditions for the peak profiling
measurements that were used in this report. For instance, in order to mimic physiological
conditions, all peak profiling experiments were performed at 37 °C and at pH 7.4. The
concentrations of the injected solutes were also considered. It is known from previous work
that the concentration of an injected solute can affect the apparent dissociation rate constant
that is obtained by the peak profiling method [9,10,22]. Ideally, this sample concentration
should represent linear elution conditions but should still provide a sufficient signal for the
reliable measurement of an injected solute's retention time and peak variance [9,10].
The effects of varying the sample concentration of carbamazepine on the measured retention
time and variance for this solute on an HSA column are shown in Figure 2. These results
were obtained on a 5 cm × 4.6 mm i.d. HSA column at a flow rate of 0.5 ml/min, but similar
trends would be expected at other flow rates [9,10,22]. As the sample concentration of
carbamazepine was increased, and in particular above 25-30 μM, a decrease in the apparent
retention time and an increase in the peak variance were seen. These changes were expected
as non-linear elution conditions began to be present at the higher sample concentrations (see
Ref. [22] for a further discussion of these effects and guidelines to avoid them in peak
profiling studies). Similar experiments with sodium nitrate showed no significant change in
the measured elution time or variance for this non-retained solute (data not shown). There
was a corresponding increase in the uncertainty of the measured elution times and variances
for both carbamazepine and sodium nitrate as the sample concentration was decreased, as
illustrated by the error bars in Figure 2. Thus, as a compromise between precision and
accuracy, 25-30 μM was selected as the sample concentrations that were used in all later
work for carbamazepine and sodium nitrate.
The next stage of this study explored the use of the single flow rate method of peak profiling
method at higher flow rates and linear velocities to estimate the dissociation rate constant kd.
This was necessary because Eqn. (2) requires the use of a flow rate that is sufficiently high
to make stationary phase mass transfer the dominant process in band-broadening [9,10,22].
However, it was found in preliminary studies that a sufficiently high flow rate could not be
reached with the given columns to obtain a steady value for kd by the single flow rate
method (data not shown). Instead, only an upper estimate for kd could be made by this
approach, giving a maximum value of 5.6 (± 0.3) s-1 for carbamazepine on the HSA column.
In all further work described in this report, a method based on Eqn. (3), or related
expressions, and measurements made at multiple flow rates was instead used to overcome
the need to work at a single high flow rate when determining kd for the interaction of
carbamazepine, and imipramine, with HSA [9,10,22].
4.2. Peak Profiling on the Control Column
It was noted early in this study that carbamazepine had measurable non-specific binding to
the support used in the columns, even when no HSA was present. This type of non-specific
binding has been seen in previous work with carbamazepine on similar materials and
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columns [5,32]. Figure 3 shows some typical chromatograms that were obtained for
carbamazepine and sodium nitrate on the control column used in this study. The retention
factor for carbamazepine on this column was determined to be kcontrol = 2.45 (± 0.01),
which was found later to represent approximately 36% of the total retention measured for
carbamazepine on the HSA column after a correction had been made for the surface
coverage of the immobilized protein.
The rate of dissociation for carbamazepine from these non-specific interaction sites was
determined by carrying out peak profiling studies for this drug on the control column. This
was done by injecting both carbamazepine and sodium nitrate on the control column at flow
rates ranging from 1 to 4 ml/min, as shown in Figure 4. A plot of (HR – HM) versus u k/
(1+k)2 for this data gave a good fit to a linear response, with a correlation coefficient of
0.9768 (n = 7) being obtained. When the slope of this plot was examined according to Eqn.
(3) and a single-site binding model, the dissociation rate constant for carbamazepine with
the support control was estimated to be kd,n = 4.6 (± 0.4). This value was then used along
with the measured retention factor of carbamazepine on the same support to later correct for
the effects of these non-specific interactions when using peak profiling to examine the
dissociation of carbamazepine from the HSA column (see next section).
4.3. Peak Profiling on the HSA Column
After the dissociation of carbamazepine from the control support had been examined, peak
profiling studies were next carried out for this drug on the HSA column. Typical
chromatograms that were obtained in these studies are shown in Figure 5, in which
carbamazepine eluted at about 4.5 min at 1 ml/min and in less than 1.5 min at 4 ml/min. The
overall retention factor measured for carbamazepine on the HSA column was 5.12 (± 0.01).
However, it was also known from work in the previous section that part of this total
retention was due to non-specific interactions of carbamazepine with the support.
Figure 6 shows the results when the data for carbamazepine on the HSA column were
analyzed by using a plot of (HR – HM) versus u k/(1+k)2. A linear fit was obtained with a
correlation coefficient of 0.9954 (n = 6). It was not possible from this fit alone to distinguish
between single-site or multi-site interactions because either model would predict a linear
relationship for this type of plot, as indicated by Eqns. (3) and (4). If it was assumed that
only single-site binding was present and Eqn. (3) was used to examine these results, an
apparent dissociation rate constant of 2.6 (± 0.3) s-1 would be obtained from this plot.
However, it was known from the prior experiments with the control column that some non-
specific interactions were present, which would lead to an error in an estimate of kd that was
based on only a single-site model for the HSA column. The next phase of this work, as
described in Section 4.4, sought to combine the results for the control column and HSA
column to make a correction for the contribution of these non-specific interactions in the
peak profiling measurements.
4.4. Corrections for Multi-site Interactions
One approach that was to correct for the contribution of the non-specific interactions was to
assume that the contribution of these sites to the overall retention of carbamazepine was the
same on the control column and HSA column. This assumption neglected the fact that the
immobilization of HSA will block some of these non-specific sites. Such an assumption was
made by setting fHSA approximately equal to zero in Eqns. (5) and (6). This approach was
useful in obtaining an initial lower estimate of kd for the interaction of carbamazepine with
HSA. In this case, the value of αn in Eqn. (6) was found by simply using the ratio of the
measured retention factors for carbamazepine on the control column and the HSA column.
This method gave an estimate for αn of 0.46 (± 0.02) and a corresponding value for αHSA of
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0.54 (± 0.02) based on Eqn (7). These fractions were then used in Eqn. (4) along with data
from Figure 5, the measured retention factors for carbamazepine on the HSA and control
columns, and the dissociation rate constant estimated in Section 4.2 for carbamazepine on
the control support. The result was an estimated dissociation rate constant for carbamazepine
with HSA of 1.4 (± 0.1) s-1, a value which now contained a correction for non-specific
binding but not for the surface coverage of HSA on the support.
A second, more detailed correction was next made that did consider the fact that some of the
non-specific interactions were blocked in the presence of immobilized HSA. This correction
was made by utilizing the measured protein content of the HSA support and a cross sectional
area for a single HSA molecule of 5600 Å2 [1,27]. This information gave a value for αHSA
of 0.63 (± 0.02) and a revised estimate for αn of 0.37 (± 0.02). When these numbers were
used along with the data from Figure 5, the measured retention factors for carbamazepine on
the HSA and control columns, and the estimated dissociation rate constant for
carbamazepine on the column support, the corrected kd value for carbamazepine with HSA
was 1.7 (± 0.2) s-1. This value was slightly higher (i.e., 18%) than the value obtained when
no correction for the coverage of HSA was made and represented the best estimate of the
dissociation rate constant for carbamazepine with HSA. Based on this value of kd and a
previously-measured association equilibrium constant of 5.3 (± 0.8) × 103 M-1 that has been
reported under similar experimental conditions for carbamazepine at Sudlow site II (i.e., the
single major binding site for carbamazepine on HSA) [5], the corresponding association rate
constant for carbamazepine at the same site on HSA was determined to be 9.0 (± 1.7) × 103
M-1 s-1.
Although there are no known previous studies that have examined the dissociation rate of
carbamazepine from HSA and there are no standard methods that could be used to easily
examine the kinetics of this interaction, the results obtained in this report do agree with rate
constants that have been measured for other solutes with HSA. For example, L-tryptophan is
a solute that also binds to Sudlow site II of HSA and that has an association equilibrium
constant only slightly higher than the value for carbamazepine at this site (i.e., 1.1 × 104 M-1
versus 5.3 × 103 M-1) [5,23]. In the case of L-tryptophan, dissociation rate constants in the
range of 3 to 6 s-1 have been reported with HSA when using methods such as stopped flow
fluorescence analysis, band-broadening studies and peak profiling [9,16,22]. These results
are similar to the final value of 1.7 s-1 that was estimated in this report for the dissociation of
carbamazepine from HSA.
4.5. Peak Profiling Studies with Imipramine
The general approach used in this study to examine carbamazepine-HSA dissociation was
also explored for use with imipramine. Like carbamazepine, imipramine was found to have
appreciable levels of non-specific binding to the support used in these studies. The retention
factor on the control column was 14.5 (± 0.3) for imipramine and made up roughly 32% of
the total retention seen for this drug on the HSA columns.
The dissociation rate of these non-specific interactions was studied by first carrying out peak
profiling experiments for imipramine on a control column and analyzing these data
according to Eqn. (3). In this case it was found that imipramine gave a best-fit line with a
slope that was statistically equal to zero (i.e., a slope that agreed with a reference value of
zero when compared at the 95% confidence level). This result indicated that the dissociation
rate constant for the non-specific interactions of this particular drug with the support was
larger than could be determined directly when using peak profiling. It was possible,
however, to obtain a lower limit for this dissociation rate constant by using either the slope
of a plot that was prepared according to Eqn. (3) or by using both this slope and its
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associated precision. These approaches gave an estimated value for kd,n of at least 130 s-1,
which represented fast dissociation of imipramine from non-specific sites on the support.
The next set of experiments used peak profiling to determine the dissociation rate constant
for imipramine on an HSA column. The plot of (HR - HM) vs. u k/(1+k)2 that was obtained
for this drug is provided in Figure 7. This plot was found to give good linear behavior, with
a correlation coefficient of 0.972 (n = 7) and only a random distribution of the residuals
about the best-fit line. If it was assumed that only single-site binding was present and Eqn.
(3) was used to examine these results, the apparent dissociation rate constant that was
obtained from the slope of the plot for imipramine on the HSA column was 1.28 (± 0.01) s-1
(see Table 1). However, it was also known that these interactions included both non-specific
binding by the drug to the support and binding by this drug with HSA. Thus, corrections for
these non-specific interactions were next made by using the same techniques as described in
Section 4.4 for carbamazepine.
It was first assumed when correcting for the non-specific interactions that the contribution of
non-specific interactions to the overall retention of imipramine was the same on the control
column and HSA column, or that fHSA was approximately equal to zero in Eqns. (5) and (6).
This method gave values of αn = 0.68 (± 0.02) and αHSA = 0.32 (± 0.02) for imipramine. The
resulting dissociation rate constant that was then estimated for imipramine with HSA by this
approach was 0.41 (± 0.04) s-1. The second approach used to correct for the non-specific
interactions made an adjustment for the fact that some of the non-specific interactions were
blocked in the presence of immobilized HSA, as described in the previous section. The
value of αHSA that was estimated by this approach was 0.52 (± 0.03) for imipramine. The
dissociation rate constant calculated by this method was 0.67 (± 0.04) s-1 for imipramine and
represented the best-estimate that was made for this parameter in this study.
The dissociation rate constant determined in this report for imipramine with HSA was close
to a value of 0.29 (±0.11) s-1 that has been recently estimated by using a peak decay method
with a similar HSA support [33]. This dissociation rate constant also agrees with estimated
kd values of 0.35 s-1 to 0.66 s-1 that have been reported for warfarin with HSA [15,20,33], a
system with a similar affinity to that present in the interaction of imipramine with HSA [7].
Based on a dissociation rate constant of 0.67 (± 0.04) s-1 and an association equilibrium
constant of 1.6 (± 1.0) × 105 M-1 for imipramine at its high affinity site on HSA [7], the
corresponding association rate constant for imipramine with HSA was calculated to be 1.1
(± 0.7) × 105 M-1 s-1.
5. CONCLUSION
The peak profiling method was used in this study to determine the dissociation rate
constants for the drugs carbamazepine and imipramine with both immobilized HSA and a
control support. This work was carried out with a method that used retention times and peak
variances that were acquired over a range of flow rates. It was shown how this method could
be used in a system with multi-site interactions and to correct for the effects of non-specific
binding in drug-protein binding studies (see summary of results in Table 1). The final
estimates obtained for the dissociation rate constant of carbamazepine and imipramine with
HSA showed good agreement with values reported for HSA with other solutes (i.e., L-
tryptophan or warfarin) or that had been obtained for the same interactions by other methods
[9,15,16,20,22,33]. This information should lead to a better understanding of how
carbamazepine and imipramine are transported in the circulation.
The peak profiling method that was described in this work is not limited to carbamazepine
and imipramine or HSA but should be suitable for use as a relatively fast and accurate
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method for studying the kinetics of other drug-protein interactions [9,10,22]. For instance,
the technique for dealing with multi-site systems that was developed in this report could be
utilized in situations other than those that involve specific binding to a protein and non-
specific binding to a support. The same approach could be used to examine the dissociation
rates for a solute from both a specific, saturable binding site and non-specific, high capacity
or non-saturable regions on a protein. This latter type of study could be carried out by
conducting peak profiling experiments for the solute in the presence and absence of a mobile
phase that contains a sufficient concentration of a site-specific probe that can be used to
saturate and block the specific sites during part of the study. A similar strategy using site-
selective probes could be used to examine the dissociation of a solute from a protein with
multiple binding sites, as might be needed to examine a drug that binds to both Sudlow sites
I and II of HSA. The applications tested in this study and these other possible uses of this
approach indicate that peak profiling should be a valuable tool in the future study of multi-
site interactions in pharmaceutical and biochemical research.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Structures of carbamazepine and imipramine.
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Figure 2.
Effects of sample concentration on (a) the measured retention times and (b) measured peak
variances for carbamazepine on an HSA column at 0.5 ml/min. The error bars in these plots
represent a range of ± 1 S.D. for triplicate injections.
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Figure 3.
Typical chromatograms for (a) carbamazepine and (b) sodium nitrate on a control column at
flow rates (bottom-to-top) of 1, 2, 3, and 4 ml/min.
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Figure 4.
Plot prepared according to Eqn. (3) for injections of carbamazepine and sodium nitrate on
the control column. The equation for the best-fit line is y = (0.435 ± 0.043) x – (0.0255 ±
0.0027), with a correlation coefficient of 0.9768 (n = 7). The error bars represent a range of
± 1 S.D. for triplicate injections.
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Figure 5.
Typical chromatograms for (a) carbamazepine and (b) sodium nitrate on the HSA column at
flow rates (bottom-to-top) of 1, 2, 3, and 4 ml/min.
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Figure 6.
Plot prepared according to either Eqn. (3) or Eqn. (4) for injections of carbamazepine and
sodium nitrate on the HSA column. The equation for the best-fit line is y = (0.6351 ±
0.0307) x – (0.0121 ± 0.0011), with a correlation coefficient of 0.9954 (n = 6). The error
bars represent a range of ± 1 S.D. for triplicate injections.
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Figure 7.
Plot prepared according to Eqns. (3) or (4) for injections of imipramine and sodium nitrate
on the HSA column. The equation for the best-fit line was y = 1.56 (± 0.017) x + 0.034 (±
0.002), with a correlation coefficient of 0.972 (n = 7). The error bars represent a range of ± 1
S.D. for triplicate injections.
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Table 1
Estimated dissociation rate constants for carbamazepine and imipramine with HSA at 37 °C and pH 7.4
Data analysis method
Dissociation rate constant, kd (s-1)a
Carbamazepine Imipramine
Single-site model 2.6 (± 0.3) 1.28 (± 0.01)
Two-site model (no correction for surface coverage of HSA) 1.4 (± 0.1) 0.41 (± 0.04)
Two-site model (with correction for surface coverage of HSA) 1.7 (± 0.2) 0.67 (± 0.04)
a
The values in parentheses represent a range of ± 1 S.D., as determined from the precision of the measured slope in plots prepared according to
Eqns. (3)-(4) and by using error propagation.
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SUPPORTING INFORMATION 
Derivation of Eqn. (4).  It is possible by using mass balance to estimate the individual 
contributions to the plate height due to stationary phase mass transfer (Hk) for a system with 
multi-site interactions, as originally proposed by Giddings [1].  This can be accomplished by 
describing the binding regions in a column as a set of distinct interaction sites, each of which has 
its own association rate constant (ka) and dissociation rate constant (kd) for an analyte A, as 
shown below.  
          ka,1 
Soluble analyte    A1 ⇄   A2             (A1) 
kd,1 
 
        ka,2 
       A1 ⇄   A3         (A2) 
kd,2 
   : 
        ka,n-1 
        A1  ⇄   An          (A3) 
kd,n-1 
 
In this model there are n possible states for the analyte.  State A1 represents the soluble analyte in 
the mobile phase, while states A2 through An represent the analyte that is bound to a series of 
unique sites (i.e., 1 to n – 1 types of sites).  To simplify this model, it is assumed that once the 
analyte has been bound by one of these sites, it cannot bind to a different site at the same time.  
The only way A can go from one type of bound state to another is by first being released from 
the first site, entering the soluble state A1 in the mobile phase, and then interacting with another 
site to form a new bound state.   
The relative mole fraction of the analyte in each state can be represented by the terms X1 
through Xn, where the summation of all X values must be equal to one.  These fractions can also 
be related to the overall observed retention factor for the analyte (k) by using mass balance, 
where the term ki represents the contribution to the overall retention factor due to the interaction 
2 
 
of A at a particular type of site I, where ki = (mol A in state Ai bound at site i)/(mol A present as 
state A1 in mobile phase). 
 
i
1 2 n
2
1
1
(1 ) 1
n
i
k
X X X
k k
    
 
    (A4)    
The following plate height equation for stationary phase mass transfer has been previously 
derived to describe a system with multi-site binding, as given in Eqns. (A1)-(A3) [1]. 
i
k 1
2 d,i
H 2 u
k
n
i
X
X

         (A5) 
Substitution of Eqn. (A4) into Eqn. (A5) yields the expression shown in Eqn. (A6). 
 
i
k 2
2 d,i
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H 2 u
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k
k 
 

     (A6) 
Eqn. (A6) can then be rewritten in the form given in Eqn. (A7) by defining i as the fraction of 
the total retention factor that is due to the interaction of A at site i, where i = ki/k. 
 
i
k 2
2 d,i
α
H 2 u
k1
n
i
k
k 
 

     (A7) 
One useful feature of Eqn. (A7) is it can be expanded to include a system with any number of 
unique binding sites (e.g., i = 2 through n, or a total of n - 1 separate binding regions for a system 
with n possible states for A).   
 It has been shown previously that the relationship (HR – HM) = Hk is valid if all plate 
height contributions except Hk are the same or negligible when comparing the band-broadening 
for retained and non-retained solutes [2].  In this situation, Eqn. (A7) predicts that a plot of (HR - 
HM) versus 
 
2
u
1
k
k


 will give a slope of i
d,i d,l,app
2 α 2
k k

  , where kd,app is the apparent 
dissociation rate constant predicted for a system with only a single type of binding site for the 
kd,app 
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analyte.  From this slope, the value of kd,i for the site of interest can be obtained by using the 
definition of i, as given earlier, and the fact that 1 = iα  if k, ki and kd,i for all other binding 
sites in the system are known or can be independently measured.  
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